TNFRSF17 and plasma cell myeloma: <b>Objective:</b> The aim of this comprehensive review and meta-analysis was to summarize the effectiveness and safety of anti-BCMA CAR-T treatment for patients with relapsed/refractory multiple myeloma (RRMM).